Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 24, 2014, 11:37:23 AM

Login with username, password and session length


Members
  • Total Members: 23024
  • Latest: louis80
Stats
  • Total Posts: 631728
  • Total Topics: 47824
  • Online Today: 266
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: GSK's new Integrase Inhibitor  (Read 1057 times)

0 Members and 1 Guest are viewing this topic.

Offline Matts

  • Member
  • Posts: 205
GSK's new Integrase Inhibitor
« on: August 10, 2009, 04:16:54 PM »
A study for treatment-naives and one for salvage patients At QuestClinical:

"The data from GSK's 10 day proof of concept study was just presented at the International AIDS Meeting in South Africa. The results show a whopping 2.5 log decrease in viral load, setting a new standard of potency for an HIV drug. This integrase inhibitor appears very well tolerated and is administered once/day without the need for a PK booster.

 We'd also like to alert you that 2 further studies of this agent will be opening shortly, one for treatment-naives and one for salvage patients.

 The naive study will compare 3 arms of once/day integrase (+ 2 nucs) versus Atripla and will run for 96 weeks.

 The salvage study is premised on the observation that GSK's integrase retains laboratory activity against raltegravir-resistant virus and will be open to salvage patients who have documented or current raltegravir resistance and at least one other fully active agent to use in the background regimen. This crucial study is slated to start enrolling in September.

 Both studies are now accepting names of patients who may be interested.

 As always, please feel free to contact me with any questions. If you prefer to be removed from this email list, simply reply with the word “remove.”

 
With kind regards,

 
Dr. Jay,

drjay@questclinical.com

415-353-0800 "

tivicay/kivexa

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.